Published 2 days ago • loading... • Updated 2 days ago

HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P

Ivonescimab combined with chemotherapy achieved a median progression-free survival of 11.14 months, with a hazard ratio of 0.60, indicating significant benefits over tislelizumab treatment.
The HARMONi-6 study included 532 patients, with 92.3% having stage IV disease, showing consistent benefits across different PD-L1 expression levels.
The study results were presented by Professor Lu Shun at the 2025 ESMO Presidential Symposium, indicating a favorable safety profile for ivonescimab with no new safety signals.
Positive results from this study led to plans for a supplemental New Drug Application review in China for ivonescimab as first-line therapy for advanced squamous non-small cell lung cancer.

Insights by Ground AI

35 Articles

HARMONi-6 mPFS 11.14 Months (HR=0.6, P

Ivonescimab plus chemotherapy demonstrated a median PFS of 11.14 months, PFS HR=0.60, P The absolute difference in median PFS between the two groups was 4.24 months (ΔPFS = 4.24...

2 days ago·Manila, Philippines

Read Full Article

LoudounTimes.com

+33 Reposted by 33 other sources

Center

HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P

Ivonescimab plus chemotherapy demonstrated a median PFS of 11.14 months, PFS HR=0.60, P < 0.0001.The absolute difference in median PFS between the two groups was 4.24 months (ΔPFS = 4.24

2 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year